Long-term efficacy and safety of levonorgestrel-releasing intrauterine system as a maintenance treatment for endometriosis
This study evaluated the efficacy and feasibility of long-term use of levonorgestrel releasing intrauterine system (LNG-IUS) in endometriosis patients after using LNG-IUS for>5 years as their postoperative maintenance therapy.
Data were obtained retrospectively from patients who maintained medical therapy for>5 years after surgical treatment of endometriosis from January 2008 to April 2015. Patients were divided into study group and control group according to the type of medication; the study group consisted of patients who received LNG-IUS as maintenance therapy, and patients in the control group received combined ...
Source: Medicine - March 11, 2022 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
New Contraception Update — Annovera, Phexxi, Slynd, and Twirla
AbstractPurpose of ReviewIn this review, we discuss the efficacy, safety, and benefits of four new contraceptive products available in the USA, specifically Annovera, Phexxi, Slynd, and Twirla.Recent FindingsAnnovera is a vaginal ring releasing ethinyl estradiol and segesterone acetate that can be used for up to one year (13 cycles), offering patients an effective, user-controlled option that may improve contraceptive access for those in low-resource settings or those with barriers to retrieving monthly prescriptions; however, given limited efficacy and safety data in people with body mass index (BMI) > 29 kg/m2,...
Source: Current Obstetrics and Gynecology Reports - January 6, 2022 Category: OBGYN Source Type: research
Combined Oral Contraceptives and Venous Thromboembolism: Review and Perspective to Mitigate the Risk
Many factors must be considered and discussed with women when initiating a contraceptive method and the risk of venous thromboembolism (VTE) is one of them. In this review, we discuss the numerous strategies that have been implemented to reduce the thrombotic risk associated with combined oral contraceptives (COCs) from their arrival on the market until today. Evidences suggesting that COCs were associated with an increased risk of VTE appeared rapidly after their marketing. Identified as the main contributor of this risk, the dosage of the estrogen, i.e., ethinylestradiol (EE), was significantly reduced. New progestins we...
Source: Frontiers in Endocrinology - December 10, 2021 Category: Endocrinology Source Type: research
Efficacy of dienogest vs combined oral contraceptive on pain associated with endometriosis: Randomized clinical trial
CONCLUSIONS: Dienogest (2 mg/day) is comparable to the COC Yasmin for the relief of endometriosis-associated pelvic pain and improvement in HRQoL.CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov under number NCT04256200; date of registration 15/1/2020 (registered retrospectively).PMID:34826668 | DOI:10.1016/j.ejogrb.2021.10.029 (Source: Reproductive Biology)
Source: Reproductive Biology - November 26, 2021 Category: Reproduction Medicine Authors: Lina El Taha Antoine Abu Musa Dalia Khalifeh Ali Khalil Sehrish Abbasi Joseph Nassif Source Type: research
Efficacy of dienogest vs combined oral contraceptive on pain associated with endometriosis: Randomized clinical trial
CONCLUSIONS: Dienogest (2 mg/day) is comparable to the COC Yasmin for the relief of endometriosis-associated pelvic pain and improvement in HRQoL.CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov under number NCT04256200; date of registration 15/1/2020 (registered retrospectively).PMID:34826668 | DOI:10.1016/j.ejogrb.2021.10.029 (Source: Reproductive Biology)
Source: Reproductive Biology - November 26, 2021 Category: Reproduction Medicine Authors: Lina El Taha Antoine Abu Musa Dalia Khalifeh Ali Khalil Sehrish Abbasi Joseph Nassif Source Type: research
Efficacy of dienogest vs combined oral contraceptive on pain associated with endometriosis: randomized clinical trial
To compare the efficacy of dienogest with the combined oral contraceptive pill (COC) Yasmin for the control of endometriosis-associated pelvic pain.Study designSeventy women with endometriosis-associated chronic pelvic pain, dysmenorrhoea or both for>6 months were randomized to either dienogest (Visanne) 2 mg/day or monophasic COC (Yasmin, 0.03 mg ethinyl estradiol and 3 mg drospirenone) for 24 weeks. The primary efficacy variable was change in non-cyclic pelvic pain and dysmenorrhoea from baseline to end of treatment, assessed using a visual analogue scale (VAS). (Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology)
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - October 30, 2021 Category: OBGYN Authors: Lina El Taha, Antoine Abu Musa, Dalia Khalifeh, Ali Khalil, Sehrish Abbasi, Joseph Nassif Source Type: research
IJERPH, Vol. 18, Pages 10607: Health Status Is Affected, and Phase I/II Biotransformation Activity Altered in Young Women Using Oral Contraceptives Containing Drospirenone/Ethinyl Estradiol
Erasmus
Combined oral contraceptive (COC) use has been associated with various adverse effects. Formulations containing drospirenone (DRSP) and ethinyl estradiol (EE) are generally regarded as milder COCs. Whether long term use of these pills indeed has a low health risk remains questionable. COC use may affect the biotransformation balance by increasing the toxic load or by interfering with the pharmacokinetics of other drugs. This may negatively impact overall health via the production of toxic biotransformation metabolites and induction of oxidative stress. Although individual enzymes involved in biotransformation a...
Source: International Journal of Environmental Research and Public Health - October 10, 2021 Category: Environmental Health Authors: Gerda Venter Carien L. van der van der Berg Francois H. van der van der Westhuizen Elardus Erasmus Tags: Article Source Type: research
The Effect of Combined Oral Contraceptive Pills on Beclin-1 and LC3B Transcript Levels in Ovarian Endometrioma
CONCLUSIONS: Oral COC pills for 6 weeks continuously before surgery decreased the eutopic endometrial expression (mRNA) of the BECN1 gene compared to those from healthy normal women and nontreated patients with an endometriotic cyst. The change in the expression of autophagy-related genes was more distinct in eutopic than ectopic endometria. This trial is registered with TCTR20170720002. Registered and enrolled the first patient on 20 July 2017.PMID:34258264 | PMC:PMC8260293 | DOI:10.1155/2021/5519538 (Source: Biomed Res)
Source: Biomed Res - July 14, 2021 Category: Research Authors: Wanwisa Waiyaput Ongarj Bovornsakulvong Srithean Lertvikool Areepan Sophonsritsuk Source Type: research
Estetrol/Drospirenone (Nextstellis) - A New Combination Oral Contraceptive
Date: June 28, 2021
Issue #:
1627Summary:
The FDA has approved a combination oral
contraceptive containing the estrogen estetrol and the
progestin drospirenone (Nextstellis– Mithra/Mayne).
Estetrol is the first new estrogen to become available
in the US in 50 years. Drospirenone is available alone(Slynd) and in combinations with the estrogen ethinyl
estradiol for prevention of pregnancy. (Source: The Medical Letter)
Source: The Medical Letter - May 19, 2021 Category: Drugs & Pharmacology Authors: admin Tags: Drospirenone estetrol Estrogens etonogestrel Medroxyprogesterone Nexplanon Nextstellis Oral contraceptives Progestins Slynd Source Type: research
Knowledge and beliefs about the use/abuse of oral contraceptive pills among males: A mixed-method explanatory sequential study in community pharmacy settings
ConclusionThis study provided insight into unexpected uses of OCPs by males in Jordan. Community pharmacists have a crucial role in the management of OCPs use and abuse. However, restricted regulations and monitoring must be released and implemented on the community to limit such practices. (Source: PLoS One)
Source: PLoS One - May 7, 2021 Category: Biomedical Science Authors: Muna Barakat Source Type: research
Risk of sexual dysfunction with progestin-based contraceptives in women of child-bearing age
ConclusionOur study found an increase in the use of levonorgestrel (COC and IUD), drospirenone, and medroxyprogesterone in subjects with SD. The risk of contraceptives did not differ when compared with oral levonorgestrel. The small association size and lack of difference between drug formulations suggest a minimal impact of progestin-based contraceptives on sexual dysfunction. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - January 1, 2021 Category: Drugs & Pharmacology Source Type: research
Uterine bleeding with hormone therapies in menopausal women: a systematic review.
Uterine bleeding with hormone therapies in menopausal women: a systematic review.
Climacteric. 2020 Sep 07;:1-9
Authors: Pickar JH, Archer DF, Goldstein SR, Kagan R, Bernick B, Mirkin S
Abstract
Uterine bleeding is a common reason why women discontinue menopausal hormone therapy (HT). This systematic review compared bleeding profiles reported in studies for continuous-combined HT approved in North America and Europe for moderate to severe vasomotor symptoms in postmenopausal women with a uterus. Non-head-to-head studies showed that uterine bleeding varies by formulation and admin...
Source: Climacteric - September 6, 2020 Category: Geriatrics Authors: Pickar JH, Archer DF, Goldstein SR, Kagan R, Bernick B, Mirkin S Tags: Climacteric Source Type: research
